NewLink Genetics Corporation (NASDAQ:NLNK) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday, July 29th.
According to Zacks, “NewLink Genetics Corporation is a biopharmaceutical company which focuses on discovering, developing and commercializing immunotherapeutic products for cancer treatment. Its portfolio also includes biologic and small-molecule immunotherapy products used for the treatment of oncology indications. NewLink Genetics Corporation is headquartered in Ames, Iowa. “
Several other analysts have also recently commented on NLNK. Cantor Fitzgerald set a $32.00 target price on NewLink Genetics Corporation and gave the company a “buy” rating in a research report on Thursday, May 4th. Jefferies Group LLC reissued a “hold” rating and set a $18.00 price objective on shares of NewLink Genetics Corporation in a research note on Monday, May 15th. Stifel Nicolaus restated a “buy” rating and issued a $26.00 target price on shares of NewLink Genetics Corporation in a report on Saturday, April 22nd. ValuEngine upgraded NewLink Genetics Corporation from a “sell” rating to a “hold” rating in a report on Friday, May 19th. Finally, Robert W. Baird restated an “outperform” rating and set a $25.00 target price on shares of NewLink Genetics Corporation in a report on Monday, June 5th. One analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $18.17.
NewLink Genetics Corporation (NLNK) traded up 0.46% during midday trading on Friday, reaching $6.62. The company’s stock had a trading volume of 113,682 shares. The company has a 50 day moving average of $7.24 and a 200-day moving average of $13.53. NewLink Genetics Corporation has a 1-year low of $5.90 and a 1-year high of $25.17. The company’s market capitalization is $194.77 million.
NewLink Genetics Corporation (NASDAQ:NLNK) last announced its quarterly earnings data on Friday, July 28th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.78) by $0.21. NewLink Genetics Corporation had a negative return on equity of 55.03% and a negative net margin of 161.94%. The firm had revenue of $10.37 million for the quarter, compared to analysts’ expectations of $2.65 million. Equities research analysts anticipate that NewLink Genetics Corporation will post ($2.82) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “NewLink Genetics Corporation (NLNK) Lifted to Hold at Zacks Investment Research” was originally posted by BBNS and is the sole property of of BBNS. If you are reading this news story on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this news story can be viewed at https://baseballnewssource.com/markets/newlink-genetics-corporation-nlnk-stock-rating-upgraded-by-zacks-investment-research-updated-updated/1308378.html.
Institutional investors have recently made changes to their positions in the stock. The Manufacturers Life Insurance Company raised its position in shares of NewLink Genetics Corporation by 3.0% in the second quarter. The Manufacturers Life Insurance Company now owns 19,069 shares of the biotechnology company’s stock valued at $140,000 after buying an additional 556 shares during the period. State Street Corp boosted its stake in shares of NewLink Genetics Corporation by 1.2% in the second quarter. State Street Corp now owns 391,464 shares of the biotechnology company’s stock valued at $2,875,000 after buying an additional 4,630 shares during the period. Tudor Investment Corp ET AL acquired a new stake in shares of NewLink Genetics Corporation during the second quarter valued at approximately $286,000. PDT Partners LLC boosted its stake in shares of NewLink Genetics Corporation by 160.2% in the second quarter. PDT Partners LLC now owns 115,795 shares of the biotechnology company’s stock valued at $851,000 after buying an additional 71,295 shares during the period. Finally, Dimensional Fund Advisors LP boosted its stake in shares of NewLink Genetics Corporation by 40.2% in the second quarter. Dimensional Fund Advisors LP now owns 120,767 shares of the biotechnology company’s stock worth $888,000 after buying an additional 34,624 shares during the last quarter. 51.42% of the stock is owned by institutional investors.
About NewLink Genetics Corporation
NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NewLink Genetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corporation and related companies with our FREE daily email newsletter.